Janssen to develop, commercialize Astellas’ ASP015K for immunologic diseases

Wednesday, October 3, 2012 09:52 AM

Janssen Biotech and Astellas Pharma have formed a license agreement whereby Janssen gains the exclusive right to develop and commercialize ASP015K, an Astellas compound, worldwide except for Japan.

ASP015K is a novel oral Janus Kinase (JAK) inhibitor which Astellas is developing for rheumatoid arthritis. In a six week phase-IIa POC study of patients with psoriasis, ASP015K was well tolerated and demonstrated dose-dependent improvements in Psoriasis Areas Severity Index (PASI) change from baseline. Astellas is currently conducting three phase-IIb studies in patients with rheumatoid arthritis in the U.S., Europe and Japan.

In return for the exclusive license to develop and commercialize ASP015K in the territory, Astellas is entitled to receive an up-front payment of $65 million from Janssen. Astellas is also eligible to receive contingent milestone payments upon the achievement of certain development, regulatory and commercial milestones, which could total up to $880 million. Astellas is further entitled to receive double-digit royalty payments on net sales of ASP015K in the territory from Janssen. After completion of the phase IIb studies in the territory, Janssen is responsible for all future costs associated with the development and commercialization of ASP015K for rheumatoid arthritis and other autoimmune indications in the territory. Astellas will continue development and commercialization of ASP015K in Japan.

Upon the execution of the license agreement, Astellas will not revise its financial forecast for the current fiscal year (from April 1, 2012 to March 31, 2013).

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 29

WCG sees ePharmaSolutions’ clinical trial portal as the next step in the data evolution, company mission

Cutting-edge advertising can ‘break through the clutter’ for successful patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs